SpringWorks Therapeutics’ (SWTX) “Buy” Rating Reaffirmed at HC Wainwright
HC Wainwright reiterated their buy rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report published on Friday,Benzinga reports. They currently have a $74.00 price objective on the stock. Several other equities analysts also recently issued reports on the company. Guggenheim cut their price objective on SpringWorks Therapeutics from $80.00 to $78.00 […]
HC Wainwright reiterated their buy rating on shares of SpringWorks Therapeutics (NASDAQ:SWTX – Free Report) in a report published on Friday,Benzinga reports. They currently have a $74.00 price objective on the stock. Several other equities analysts also recently issued reports on the company. Guggenheim cut their price objective on SpringWorks Therapeutics from $80.00 to $78.00 […]
